Our Board of Directors brings unparalleled expertise and insight, guiding our mission to revolutionize health and nutrition. They embody our core values of innovation, integrity, and excellence, ensuring our strategies not only meet but exceed industry standards.
Their collective wisdom shapes our approach to precision nutrition, driving us to deliver scientifically validated, trustworthy solutions. Under their stewardship, Chrysea is forging a path towards a healthier future, making impactful strides in wellness and preventive health.
Susan Bergin is a General Counsel at Juvenescence. Susan is a dual-qualified Solicitor and Medicinal Chemist with extensive experience in life sciences including contentious and non-contentious intellectual property, commercial law, and corporate transactions. After leaving Trinity College Dublin, where she studied Medicinal Chemistry, she worked in Nigeria, Nepal, the United States, and Canada. Susan also holds an LLM from the University of Law, a Master of Science degree in Intellectual Property Law, and a Post-Graduate Diploma in Intellectual Property Law and Practice from the University of Oxford.
Susan was an Associate at Jones Day and Marks & Clerk Law in London where she worked on high stakes patent litigation and major corporate transactions for major pharmaceutical clients including AbbVie, AstraZeneca, Celgene, Genentech, and Pfizer. Susan is also an executive board member in the group’s Irish companies and plays a key part developing and optimizing the corporate operations across the Juvenescence group.
Chief Executive Officer
Pedro is an established, highly-networked and seasoned life-sciences entrepreneur, with over 25-years track record in the biotechnology and healthcare industry.
A graduate from Kings College London he carried out research at Massachusetts Institute of Technology (MIT), the Technical University of Denmark (DTU), and Técnico Lisbon (IST); He further took a 12-months Masters Programme in Management at the University of Texas, Austin. He Founded in 1996 and sold in 2018 the Biotecnol Group of companies, RDN (biopharmaceutical products CDMO company) and Biotecnol Limited (a pioneering immuno-oncology company). Pedro was a Board Member of Vida Rhein SA, part of the Rhein Biotech NV group, developing hepatitis vaccines (sold to Dynavax, Inc) and Board Member of 4Tune Engineering, a Portuguese leading data-analytics and risk-analysis company (sold to Valgenesis, Inc). With a deal flow of over €250M in cross -border financing and transactions, including fund-raising, deal-making, M&A, Pedro brings a wealth of experience from an entrepreneurial and leadership perspective across the various components of a biotech company value-chain.
Pedro has collected over the years numerous awards for his pioneering achievements in bioentrepreneurship.